Highlights
- Congestive hepatopathy (CH) triggers a specific mechanotransduction pathway in pericentral liver sinusoidal endothelial cells (LSECs) driven by hydrostatic pressure.
- The Integrin αV-YAP signaling axis is identified as the primary sensor of mechanical stress, leading to the massive upregulation of Connective Tissue Growth Factor (CTGF).
- LSEC-derived CTGF acts as a paracrine and autocrine mediator, stimulating collagen production in both LSECs and hepatic stellate cells (HSCs).
- Inhibition of Integrin αV or endothelial-specific deletion of CTGF significantly ameliorates liver fibrosis, portal hypertension, and the development of liver cancer in preclinical models.
Background
Congestive hepatopathy (CH) is a distinct clinical entity resulting from chronic passive venous congestion of the liver, most commonly associated with right-sided heart failure, constrictive pericarditis, or the Fontan procedure for congenital heart disease. Unlike other forms of chronic liver injury such as NAFLD or viral hepatitis, which typically initiate in the periportal areas, CH is characterized by a unique pattern of pericentral (Zone 3) sinusoidal congestion and fibrosis. As the disease progresses, patients develop cardiac cirrhosis, portal hypertension, and eventually, hepatocellular carcinoma (HCC).
Despite the significant morbidity and mortality associated with Fontan-associated liver disease (FALD) and other forms of CH, the precise molecular mechanisms by which mechanical hydrostatic pressure is converted into biochemical signals for fibrogenesis have remained poorly understood. Recent advances in single-cell transcriptomics and spatial biology have now shed light on the role of liver sinusoidal endothelial cells (LSECs) as the primary mechanosensors in this process.
Key Content
Mechanotransduction in the Liver Sinusoid
The hepatic sinusoid is a unique vascular bed where LSECs form a permeable barrier between the blood flow and the space of Disse. In the setting of chronic congestion, such as that modeled by partial inferior vena cava ligation (pIVCL), there is a significant increase in hydrostatic pressure within the central veins and surrounding sinusoids. Research has shown that LSECs are particularly sensitive to these mechanical changes.
Using single-cell RNA sequencing (scRNA-seq), researchers have identified that the most significant transcriptomic changes after the induction of congestion occur in the pericentral LSECs. Specifically, genes related to the integrin signaling pathway and the Hippo pathway effector, Yes-associated protein (YAP), are markedly activated. This suggests that LSECs do not merely react to congestion but actively transduce physical pressure into pro-fibrotic signaling.
The Integrin αV-YAP-CTGF Signaling Cascade
The molecular heart of this process is the Integrin αV-YAP-CTGF axis. Experimental evidence indicates that hydrostatic pressure stimulates Integrin αV on the surface of LSECs. This activation triggers the nuclear translocation of YAP, a transcriptional co-activator known for its role in mechanobiology. Once in the nucleus, YAP drives the expression of Connective Tissue Growth Factor (CTGF), also known as CCN2.
CTGF serves as a potent pro-fibrotic cytokine. In the context of CH, it has been demonstrated that LSEC-derived CTGF leads to:
- Autocrine Effects: Upregulation of Type IV Collagen (COL4) within the LSECs themselves, contributing to the capillarization of the sinusoids.
- Paracrine Effects: Activation of neighboring hepatic stellate cells (HSCs), which in turn secrete Type I Collagen (COL1) and further COL4, creating a dense fibrotic matrix.
Translational Insights from Fontan-Associated Liver Disease
The clinical relevance of these findings is underscored by studies of human patients with FALD. Spatial transcriptomics and scRNA-seq of human liver samples from Fontan patients have confirmed that YAP activation and CTGF upregulation are localized to the pericentral LSECs. This spatial correlation reinforces the theory that the mechanical stress of the Fontan circulation mimics the pIVCL mouse model, driving a conserved fibrotic program in humans.
Portal Hypertension and Carcinogenesis
The progression of fibrosis in CH is not only a structural issue but a functional one. The accumulation of extracellular matrix increases intrahepatic resistance, leading to portal hypertension. Furthermore, the chronic inflammatory and fibrotic microenvironment induced by the YAP-CTGF axis creates a fertile ground for tumorigenesis. In animal models, the deletion of CTGF in endothelial cells was shown not only to reduce fibrosis and portal pressure but also to significantly suppress the development of liver tumors, suggesting that this pathway is a critical link between mechanical congestion and cancer.
Therapeutic Strategies: Targeting the Axis
Given the central role of Integrin αV and CTGF, pharmacological inhibition of these molecules presents a promising therapeutic avenue. Studies have shown that small molecule inhibitors or neutralizing antibodies against Integrin αV can effectively block the activation of YAP and subsequent CTGF expression, thereby halting the progression of CH-induced damage. Since there are currently no approved medical therapies specifically for FALD, targeting this mechanotransduction pathway represents a major step forward in precision medicine for cardiac-related liver disease.
Expert Commentary
The discovery of the Integrin αV-YAP-CTGF axis represents a paradigm shift in our understanding of congestive hepatopathy. For decades, CH was viewed as a passive result of ‘back-pressure.’ We now understand it as an active biological process mediated by the endothelium. The use of scRNA-seq and spatial transcriptomics has been instrumental in identifying the pericentral LSEC as the ‘ground zero’ for this pathology.
However, several questions remain. While Integrin αV is a clear trigger, the potential involvement of other integrins or mechanosensitive ion channels (like Piezo1) in LSECs cannot be entirely ruled out. Furthermore, while the preclinical data for CTGF inhibition is robust, translating this into the clinical setting for Fontan patients—who often have multi-organ complications—will require careful consideration of systemic safety profiles. Future clinical trials should focus on whether early intervention in this pathway can prevent the ‘point of no return’ in cardiac cirrhosis.
Conclusion
Chronic liver congestion leads to a devastating cascade of fibrosis, portal hypertension, and cancer. The identification of the Integrin αV-YAP-CTGF axis in LSECs provides a clear molecular mechanism for this progression and offers several potential therapeutic targets. As we move toward a more mechanistic classification of liver diseases, the ability to target the physical-to-biochemical signaling in the liver sinusoid may offer new hope for patients with heart failure and Fontan circulation. Further research into the long-term effects of Integrin αV inhibition in humans is warranted to validate these promising preclinical findings.
References
- Kato S, et al. Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy. Gastroenterology. 2026; PMID: 41758081.
- Emmi SJ, et al. Mechanotransduction in liver diseases: from molecular mechanisms to therapeutic targets. Hepatology. 2023.
- Valter KC, et al. Fontan-associated liver disease: Recent insights and future directions. J Cardiovasc Dev Dis. 2021.
